Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without ...
Fierce Biotech

Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient

In a 14-month follow-up, Sana Biotechnology has found that its investigational allogeneic cell therapy continued to produce insulin in one patient with Type 1 diabetes, with no safety concerns ...

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Results demonstrated early signals of C-peptide preservationT1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing ...
Nature

C-Peptide and Its Role in Diabetes Complications

C-peptide, a 31–amino acid peptide originally regarded as an inert by‐product of insulin synthesis, is emerging as a key modulator of diabetic complications. Secreted in equimolar amounts with insulin ...
Medscape

AID Systems Help T2D Patients Regardless of C-Peptide Levels

“A benefit of AID is present with high C-peptide levels and low C-peptide levels. Thus, requiring a low C-peptide level as a prerequisite for AID therapy is not warranted,” the authors wrote. The ...